Opthea to Participate in the Leerink Partners Global Biopharma Conference
Opthea to Participate in the Leerink Partners Global Biopharma Conference
MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; "Opthea"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.
澳大利亞墨爾本，2024年3月5日（GLOBE NEWSWIRE）——開發治療高度流行和進行性視網膜疾病的新療法的臨床階段生物製藥公司Opthea Limited（澳大利亞證券交易所股票代碼：OPT；“Opthea”）今天宣佈，管理層將參加2024年3月11日至13日在佛羅里達州邁阿密舉行的Leerink Partners全球生物製藥會議上的一對一投資者會議。
About Opthea
關於 Opthea
Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea's lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.
Opthea（澳大利亞證券交易所股票代碼：OPT；納斯達克股票代碼：OPT）是一家生物製藥公司，正在開發新療法，以滿足在治療高度流行和進行性視網膜疾病方面未得到滿足的需求，包括溼性年齡相關性黃斑變性（溼性AMD）和糖尿病性黃斑水腫（DME）。
Opthea的主要候選產品索齊尼伯西普正在兩項關鍵的3期臨床試驗（COAST，NCT04757636 和Shore，NCT04757610）中接受評估，與標準護理的抗VEGF-A單一療法聯合使用，與標準護理的抗VEGF-A藥物相比，可提高整體療效並提供卓越的視力增益。要了解更多信息，請訪問我們的網站並在 X 和 LinkedIn 上關注我們。
Authorized for release to ASX by Fred Guerard, CEO
首席執行官弗雷德·蓋拉德授權向澳大利亞證券交易所發行
Investor Enquiries
投資者查詢
PJ Kelleher
LifeSci Advisors
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
PJ Kelleher
生命科學顧問
電子郵件：pkelleher@lifesciadvisors.com
電話：617-430-7579
Media
媒體
Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com
西爾瓦娜·格爾西-莉娜
NorthStream 全球合作伙伴
silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
加入我們的電子郵件數據庫以接收計劃更新：
電話：+61 (0) 3 9826 0399
電子郵件：info@opthea.com